Results 141 to 150 of about 32,846 (250)

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction‐Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity‐management modalities exert weight‐independent hepatic effects remains uncertain.
Matteo Monami, Amanda Belluzzi, Silvio Buscemi, Luca Busetto, Ricardo Cohen, Maurizio De Luca, Andrea Galli, Edoardo Mannucci, Tarissa Z. Petry, Benedetta Ragghianti, Paolo Sbraccia, Dror Dicker   +11 more
wiley   +1 more source

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) arises from dysregulated interactions between nutrient delivery, adipose tissue lipid handling and liver lipid metabolism, which collectively coalesce to drive inflammatory signalling leading to metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis. Recent clinical
Evangelia E. Tsakiridis, Gregory R. Steinberg   +1 more
wiley   +1 more source

Unimolecular GLP‐1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta‐Cell Survival and Glycaemic Regulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To characterise the metabolic benefits of a GLP‐1/apelin hybrid peptide, namely exendin‐4‐linker‐apelin (ELA), and associated acylated forms, including ELA‐Lys12(γGluPal), ELA‐Lys27(γGluPal) and ELA‐Lys38(γGluPal). Methods Concentration‐ and receptor‐dependent effects of the peptides on insulin secretion and beta‐cell turnover were ...
Ananyaa Sridhar, Ethan S. Palmer, Sarah L. Craig, Elzbieta Krason‐Kidzinska, Nigel Irwin, Finbarr P. M. O'Harte   +5 more
wiley   +1 more source

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To describe obesity treatments in real‐world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post‐discontinuation. Materials and Methods This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida.
Hamlet Gasoyan, Rebecca Schulte, Christopher B. Boyer, Nicholas J. Casacchia, W. Scott Butsch, Phuc Le, Ali Aminian, Marcio L. Griebeler, Bartolome Burguera, Michael B. Rothberg   +9 more
wiley   +1 more source

The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function

Scientific Reports
Chronic treatment with GLP-1R agonists may moderately lower blood pressure due to increased natriuresis and RAAS inhibition. Short-term effect of these drugs on blood pressure may be opposite and its mechanism remains unclear.
Małgorzata Wajdlich, Michał Nowicki
doaj   +1 more source

Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Excess adiposity and obesity are increasingly prevalent, with incidence rising in many parts of the world; both trigger a state of metabo‐inflammation in adipose tissue, creating a systemic milieu characterised by insulin resistance and pro‐inflammatory and fibrogenic states. Along with systemic inflammatory cues, perturbations in systemic and
Mirjana Grocic, Madison Nguyen, Arun J. Sanyal   +2 more
wiley   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

Potential of liraglutide in the treatment of patients with type 2 diabetes

Vascular Health and Risk Management, 2009
Carolyn F DeaconDepartment of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, DenmarkAbstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type ...
Carolyn F Deacon
doaj  

Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model‐informed drug development (MIDD) to evaluate whether a 1.7‐mg maintenance dose provides comparable exposure, tolerability and BMI effects in adolescents versus adults and versus the 2.4‐mg ...
Anders Strathe, Eric M. Bomberg, Garrit Jensch, Jonas Kildegaard, Nina M. Harder‐Lauridsen, Daniel Weghuber, Rune Viig Overgaard   +6 more
wiley   +1 more source

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This TriNetX (US, 2016–2023) study compared clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes treated with GLP‐1 receptor agonists vs DPP4 inhibitors. ABSTRACT Objectives To evaluate whether glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are associated with improved survival and renal outcomes in patients with ...
Yu‐Ting Yu, Ying Chun Lee, Yu‐Wei Fang, Wen‐Hui Hsieh, Ming‐Hsien Tsai   +4 more
wiley   +1 more source